Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab developed and manufactured by Biocon Biologics for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/yIYOAPZ
0 Comments